Bempedoic acid and ezetimibe
Nexlizet is a prescription tablet combining bempedoic acid (180 mg) and ezetimibe (10 mg) to help lower cholesterol levels. It works by reducing cholesterol production in the liver and blocking its absorption from food. Taken orally, it's used for adults with high cholesterol who need additional treatment. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Nexlizet is a prescription tablet combining bempedoic acid (180 mg) and ezetimibe (10 mg) to help lower cholesterol levels. It works by reducing cholesterol production in the liver and blocking its absorption from food. Taken orally, it's used for adults with high cholesterol who need additional treatment. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Bempedoic acid and ezetimibe",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Bempedoic acid and ezetimibe — ANDA 211617 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211617"
}
]
|
| identifier | ANDA211617 |
| issued | 2016-09-16 |
| keyword |
[
"drug-information",
"health-care",
"medications",
"pharmaceuticals",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Bempedoic acid and ezetimibe |
